Search Results

Policy

Zydus launches Mirabegron Extended-Release Tablets in the US

Zydus Lifesciences Limited announces the launch of Mirabegron Extended-Release Tablets, 25 mg in the US market.

April 22, 2024

·

2 min read

Press Releases

Zydus announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable, contrast agents in the US

September 16, 2024

·

2 min read

Pharm Country

Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea

Enzychem Lifesciences and Cadila Healthcare Ltd, a part of the Zydus Group, announced that they have entered a Manufacturing License and Technology Transfer Agreement for the world’s first plasmid DNA vaccine.

November 26, 2021

·

3 min read

BioMidwest

PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea.

January 4, 2022

·

3 min read

Zydus receives USFDA approval for ZITUVIO™ to treat adult patients with type 2 diabetes mellitus

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as ‘Zydus’) today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIO™ (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg.

October 20, 2023

·

4 min read

Business

Zydus appoints Mr. Punit Patel as President and CEO to lead its business operations in North America

Zydus Lifesciences Limited a discovery-driven, global lifesciences company announced the appointment of Mr. Punit Patel as President and Chief Executive Officer, Americas.

October 16, 2023

·

3 min read

PharmaJet Partner Zydus Cadila Seeks EUA on World’s First Plasmid DNA COVID-19 Vaccine

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19.

July 7, 2021

·

3 min read

PharmaJet Partner Zydus Cadila Announces Emergency Use Authorization Approval for World’s First Plasmid DNA COVID-19 Vaccine

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila, has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19.

August 23, 2021

·

3 min read

Biotech Beach

Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY.

April 16, 2024

·

6 min read

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world

Zydus Cadila today announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19.

August 20, 2021

·

2 min read